Lamotrigine‐Associated Rash: Risk/Benefit Considerations in Adults and Children

1999339 citationsReview

Authors

A. Guberman · Engineering and Physical Sciences Research Council

Frank Besag · University of Ottawa

Martin J. Brodie · Western Infirmary

Joseph M. Dooley · Izaak Walton Killam Health Centre

Michael Duchowny · Boston Children's Hospital

John M. Pellock · Virginia Commonwealth University Medical Center

Alan Richens

Abstract

Recommendations are made for both minimizing the likelihood of serious rash and for management of rash in patients taking LTG. Risk of serious rash may possibly be lessened by strict adherence to manufacturer's dosing guidelines, particularly in patients who are at higher risk: those on concurrent VPA and in the pediatric population.

Topics & Keywords

Drug-Induced Adverse Reactions Pharmaceutical studies and practices Pharmacological Effects and Toxicity Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Epilepsia

Volume 40, Issue 7, pp. 985-991

DOI: 10.1111/j.1528-1157.1999.tb00807.x

Field-Weighted Citation Impact: 11.94